Holen Sie sich die Stockscreener-App
0.00
100.00%
-12.58
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Bitget
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Rare-disease drugmaker BioCryst turns first annual profit, wins FDA OK for kids - Stock Titan
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed? - Yahoo Finance
ATXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Spikes: Can Astria Therapeutics Inc ride the EV waveQuarterly Earnings Report & Community Verified Trade Signals - baoquankhu1.vn
Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition - Insider Monkey
What are the future prospects of Astria Therapeutics Inc.2025 EndofYear Setup & Weekly High Potential Stock Alerts - mfd.ru
Can Astria Therapeutics Inc. ride the EV wave2025 Earnings Surprises & Technical Analysis for Trade Confirmation - mfd.ru
Is Astria Therapeutics Inc.’s ROE strong enoughTrade Volume Summary & Weekly Sector Rotation Insights - mfd.ru
BioCryst (BCRX) Poised for Growth with Key Acquisition and Positive Outlook - GuruFocus
Can Astria Therapeutics Inc. maintain its current growth rateJuly 2025 Trends & Capital Efficiency Focused Strategies - mfd.ru
Analyst Calls: Should I invest in Astria Therapeutics Inc before earnings2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy - MSN
Biocryst expands HAE treatment portfolio with Astria acquisition - Angioedema News
Can Astria Therapeutics Inc. stock beat market expectations this quarterMarket Movement Recap & Safe Capital Growth Plans - mfd.ru
Buyout Rumor: Can Astria Therapeutics Inc ride the EV waveEntry Point & Precise Trade Entry Recommendations - baoquankhu1.vn
Published on: 2026-01-28 20:41:53 - baoquankhu1.vn
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)? - Sahm
Bearish Setup: Can Astria Therapeutics Inc. reach all time highs this yearMarket Sentiment Report & Fast Gaining Stock Reports - mfd.ru
Breakouts Watch: What dividend growth rate does Astria Therapeutics Inc offer2025 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
Liquidity Mapping Around (ATXS) Price Events - Stock Traders Daily
Option Delisting: Astria Therapeutics (ATXS) to be Delisted - GuruFocus
BioCryst Completes Acquisition of Astria Therapeutics - Longbridge
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - Sahm
Astria Therapeutics Completes Merger and Goes Private - TipRanks
Astria Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
BioCryst Completes Acquisition of Astria Therapeutics (ATXS) - GuruFocus
BioCryst completes $700 million acquisition of Astria Therapeutics - Investing.com
BioCryst completes $700 million acquisition of Astria Therapeutics By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics to Enhance HAE Portfolio - Quiver Quantitative
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
BioCryst: A Changed And Interesting Thesis For 2026 (NASDAQ:BCRX) - Seeking Alpha
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Hedge Fund Bets: Is Astria Therapeutics Inc trading at a discount2025 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Increases By 37.9% - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Why (ATXS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - MarketBeat
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® - GlobeNewswire
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - Yahoo Finance
Why Astria Therapeutics Inc. stock could outperform in 20252025 Major Catalysts & Free Long-Term Investment Growth Plans - ulpravda.ru
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - sharewise.com
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - PR Newswire
Growth Recap: Is Astria Therapeutics Inc stock in correction or buying zone2025 Trade Ideas & Consistent Profit Focused Trading Strategies - Bộ Nội Vụ
Understanding Momentum Shifts in (ATXS) - Stock Traders Daily
Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward - MSN
JMP Securities Downgrades Astria Therapeutics (ATXS) - MSN
Patterns Watch: Is Astria Therapeutics Inc stock gaining market shareMarket Performance Summary & Capital Efficiency Focused Strategies - moha.gov.vn
Astria faces shareholder lawsuits over planned BioCryst merger - MSN
5.71%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):